Actinium Pharmaceuticals and Eckert & Ziegler Collaborate on Actinium-225 Supply for Targeted Radiotherapies
New York, NY, March 24, 2025 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a pioneering biopharmaceutical company leading the development of targeted radiotherapies, has recently announced a significant collaboration with Eckert & Ziegler. This strategic agreement grants Actinium Pharmaceuticals access to Eckert & Ziegler’s high-quality Actinium-225 (Ac-225).
Advancing Targeted Radiotherapies with Ac-225
Actinium-225 is a crucial component in the production of Actimab-A, Actinium Pharmaceuticals’ lead product, which is currently undergoing clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). With this agreement, Actinium Pharmaceuticals will have a reliable and consistent supply of Ac-225 to further advance the development of Actimab-A and other potential candidates.
Expanding the Portfolio: Late-Stage and Early-Stage Development
The collaboration with Eckert & Ziegler also applies to Actinium Pharmaceuticals’ late-stage and early-stage development candidates for both U.S. and international clinical trials. The company’s pipeline includes several potential radiotherapeutic treatments for various cancers, such as Iomab-B for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. This partnership will enable Actinium Pharmaceuticals to progress these projects more efficiently and effectively.
Impact on Patients and the Medical Community
For patients, this collaboration represents a step forward in the development of targeted radiotherapies, which aim to destroy cancer cells while minimizing damage to healthy cells. The reliable supply of Actinium-225 will help ensure that these innovative treatments become available to those who need them, ultimately improving patient outcomes and quality of life.
Global Reach and Collaboration
This agreement’s implications extend beyond the United States, as Actinium Pharmaceuticals’ international clinical trials will benefit from this partnership as well. The collaboration reinforces the importance of global collaborations in advancing medical research and innovation, ultimately leading to better healthcare solutions for patients worldwide.
Conclusion
Actinium Pharmaceuticals’ collaboration with Eckert & Ziegler signifies a significant milestone in the development of targeted radiotherapies. With a reliable and consistent supply of Actinium-225, Actinium Pharmaceuticals can continue to advance its lead product, Actimab-A, as well as its late-stage and early-stage development candidates. This collaboration not only benefits Actinium Pharmaceuticals but also the medical community and, most importantly, patients in need of innovative cancer treatments. The partnership is a testament to the power of collaboration and the potential of targeted radiotherapies in transforming cancer care.
- Actinium Pharmaceuticals and Eckert & Ziegler form a strategic partnership for the supply of Actinium-225
- Actinium-225 is a critical component in the production of Actimab-A and other potential candidates
- Collaboration will enable more efficient and effective development of Actinium Pharmaceuticals’ pipeline
- Impact on patients: improved outcomes and quality of life
- Global reach: collaboration extends to international clinical trials
As the medical community continues to explore new ways to combat cancer, partnerships like this one between Actinium Pharmaceuticals and Eckert & Ziegler demonstrate the power of collaboration and the potential of targeted radiotherapies to revolutionize cancer care.
Stay informed about the latest advancements in targeted radiotherapies and cancer research by visiting Actinium Pharmaceuticals’ website and following them on social media.
